e-Therapeutics plc Announces Recruitment Resumes Into US Phase I ETS2101 Brain Cancer Trial
OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc (AIM:ETX) announces today that the US Food and Drug Administration (FDA) has approved the resumption of recruitment of new patients into the Company’s investigator-led Phase Ia study of ETS2101 in brain cancer, conducted at the University of California San Diego Moores Cancer Centre.
Help employers find you! Check out all the jobs and post your resume.